Randomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer

Vergote, IB; Van Nieuwenhuysen, E; Casado, A; Laenen, A; Lorusso, D; Braicu, I; Guerra-Alia, E; Zola, P; Wimberger, P; Debruyne, P; Falco, E; Ferrero, A; Muallem, MZ; Kerger, J; Garcia Martinez, E; Pignata, S; Sehouli, J; Van Gorp, T; GENNIGENS, Christine; Rubio Pérez, MJ

Unpublished conference/Abstract (Scientific congresses and symposiums)

Vergote, IB; Van Nieuwenhuysen, E; Casado, A et al.

2021 • Int J Gynecol Cancer: first published as 10.1136/ijgc-2021-ESGO.16

Permalink
https://hdl.handle.net/2268/264510

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

POSTER 199.pdf

Publisher postprint (76.76 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Paclitaxel-Carboplatin; Nintedanib; cervical cancer

Disciplines :

Oncology

Author, co-author :

Vergote, IB

Van Nieuwenhuysen, E

Casado, A

Laenen, A

Lorusso, D

Braicu, I

Guerra-Alia, E

Zola, P

Wimberger, P

Debruyne, P

More authors (10 more)

Language :

English

Title :

Randomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer

Publication date :

12 October 2021

Event name :

Int J Gynecol Cancer: first published as 10.1136/ijgc-2021-ESGO.16

Event date :

12 octobre 2021

Available on ORBi :

since 26 October 2021

Statistics

Number of views

45 (4 by ULiège)

Number of downloads

48 (3 by ULiège)

More statistics